Share this article
Share this article
ROCHESTER, N.Y., Jan. 7, 2021 /PRNewswire/ OyaGen, Inc. announced today publication in VIRUSES, a peer reviewed journal, of studies carried out by OyaGen in collaboration with NIH/NIAID Integrated Research Facility at Fort Detrick MD. This Study identified OYA1 as a highly effective antiviral against several viruses including Ebola and Lassa viruses.
Bennett et al., A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures. (2021)
About OYA1. OYA1 (a.k.a. sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. The published study results showed that OYA1 was highly effective in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID. The data also suggest that OYA1 could be significantly more potent than Gilead Science s remdesivir. In vitro studies showed that when OY
The total number of COVID-19 cases reported in Los Angeles County for the two day span of Dec. 25 and 26 totaled nearly 30,000, according to the LA County Health Department.
Transmission electron micrograph of SARS-CoV-2 virus particles isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland.
Image/NIAID
Officials confirmed 142 new deaths and 29,464 new cases of confirmed COVID-19. The numbers today reflect 13,185 cases reported today and 15,538 cases from yesterday along with 131 deaths Friday and 5 deaths reported Saturday.
6,770 people were hospitalized with COVID-19, and 20% of these people are in the ICU, health officials said Saturday.